Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Lauren H. Boal"'
Autor:
Rosandra N. Kaplan, Brigitte C. Widemann, Seth M. Steinberg, David J. Liewehr, Christianne Persenaire, Melinda S. Merchant, Daniel W. Beury, Mark Ahlman, Eva Dombi, Joanne Derdak, Miki Kasai, Melissa Spencer, John Glod, Lauren H. Boal
Supplemental Statistical Section for Pharmacokinetic and Pharmacodynamic studies
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1cadc7503c20a833dc62ce205b6bb610
https://doi.org/10.1158/1078-0432.22476909.v1
https://doi.org/10.1158/1078-0432.22476909.v1
Autor:
Rosandra N. Kaplan, Brigitte C. Widemann, Seth M. Steinberg, David J. Liewehr, Christianne Persenaire, Melinda S. Merchant, Daniel W. Beury, Mark Ahlman, Eva Dombi, Joanne Derdak, Miki Kasai, Melissa Spencer, John Glod, Lauren H. Boal
Supplemental appendix and tables
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::09ed0d3bd740a360d910963450dffc77
https://doi.org/10.1158/1078-0432.22476912.v1
https://doi.org/10.1158/1078-0432.22476912.v1
Autor:
Rosandra N. Kaplan, Brigitte C. Widemann, Seth M. Steinberg, David J. Liewehr, Christianne Persenaire, Melinda S. Merchant, Daniel W. Beury, Mark Ahlman, Eva Dombi, Joanne Derdak, Miki Kasai, Melissa Spencer, John Glod, Lauren H. Boal
Purpose:Simultaneously targeting the tumor and tumor microenvironment may hold promise in treating children with refractory solid tumors. Pexidartinib, an oral inhibitor of tyrosine kinases including colony stimulating factor 1 receptor (CSF-1R), KIT
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4a40581dd3058299048b2429dbf2c4b5
https://doi.org/10.1158/1078-0432.c.6529521
https://doi.org/10.1158/1078-0432.c.6529521
Autor:
Melissa Spencer, Seth M. Steinberg, Eva Dombi, John Glod, Rosandra N. Kaplan, Melinda S. Merchant, Joanne Derdak, Lauren H Boal, Miki Kasai, Christianne Persenaire, Brigitte C. Widemann, Daniel W Beury, Mark A. Ahlman, David J. Liewehr
Publikováno v:
Clin Cancer Res
Purpose: Simultaneously targeting the tumor and tumor microenvironment may hold promise in treating children with refractory solid tumors. Pexidartinib, an oral inhibitor of tyrosine kinases including colony stimulating factor 1 receptor (CSF-1R), KI